Clinical Trial Update: XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

View source ↗

Summary

Post-marketing trial update for XIENCE PRIME SV Everolimus-eluting coronary stent in Japan shows completion with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Coronary Artery Occlusion
• Ischemic Heart Disease
• Myocardial Ischemia

Drugs mentioned

• XIENCE PRIME SV (everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Ischemic Heart Disease, Angina Pectoris | Status: COMPLETED | Results posted: 2019-07-22